These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Real-world comparison of effectiveness between tofacitinib and vedolizumab in patients with ulcerative colitis exposed to at least one anti-TNF agent. Buisson A; Nachury M; Guilmoteau T; Altwegg R; Treton X; Fumery M; Serrero M; Leclerc E; Caillo L; Pereira B; Amiot A; Bouguen G Aliment Pharmacol Ther; 2023 Mar; 57(6):676-688. PubMed ID: 36401585 [TBL] [Abstract][Full Text] [Related]
8. Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease. Rosario M; French JL; Dirks NL; Sankoh S; Parikh A; Yang H; Danese S; Colombel JF; Smyth M; Sandborn WJ; Feagan BG; Reinisch W; Sands BE; Sans M; Fox I J Crohns Colitis; 2017 Aug; 11(8):921-929. PubMed ID: 28333288 [TBL] [Abstract][Full Text] [Related]
9. Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis. Faleck DM; Winters A; Chablaney S; Shashi P; Meserve J; Weiss A; Aniwan S; Koliani-Pace JL; Kochhar G; Boland BS; Singh S; Hirten R; Shmidt E; Kesar V; Lasch K; Luo M; Bohm M; Varma S; Fischer M; Hudesman D; Chang S; Lukin D; Sultan K; Swaminath A; Gupta N; Siegel CA; Shen B; Sandborn WJ; Kane S; Loftus EV; Sands BE; Colombel JF; Dulai PS; Ungaro R Clin Gastroenterol Hepatol; 2019 Nov; 17(12):2497-2505.e1. PubMed ID: 30625408 [TBL] [Abstract][Full Text] [Related]
10. A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's disease. Dulai PS; Amiot A; Peyrin-Biroulet L; Jairath V; Serrero M; Filippi J; Singh S; Pariente B; Loftus EV; Roblin X; Kane S; Buisson A; Siegel CA; Bouhnik Y; Sandborn WJ; Lasch K; Rosario M; Feagan BG; Bojic D; Trang-Poisson C; Shen B; Altwegg R; Sands BE; Colombel JF; Carbonnel F; Aliment Pharmacol Ther; 2020 Mar; 51(5):553-564. PubMed ID: 31867766 [TBL] [Abstract][Full Text] [Related]
11. Comparative effectiveness of antitumour necrosis factor agents and vedolizumab in ulcerative colitis. Davis R; McParland P; Dodd S; Storey D; Probert C; Collins P; Skouras T; Steel A; Derbyshire E; Dibb M; Subramanian S Eur J Gastroenterol Hepatol; 2019 Jun; 31(6):661-667. PubMed ID: 30855421 [TBL] [Abstract][Full Text] [Related]
12. Influence of Drug Exposure on Vedolizumab-Induced Endoscopic Remission in Anti-Tumour Necrosis Factor [TNF] Naïve and Anti-TNF Exposed IBD Patients. Verstockt B; Mertens E; Dreesen E; Outtier A; Noman M; Tops S; Schops G; Van Assche G; Vermeire S; Gils A; Ferrante M J Crohns Colitis; 2020 Mar; 14(3):332-341. PubMed ID: 31504343 [TBL] [Abstract][Full Text] [Related]
13. Expression Levels of 4 Genes in Colon Tissue Might Be Used to Predict Which Patients Will Enter Endoscopic Remission After Vedolizumab Therapy for Inflammatory Bowel Diseases. Verstockt B; Verstockt S; Veny M; Dehairs J; Arnauts K; Van Assche G; De Hertogh G; Vermeire S; Salas A; Ferrante M Clin Gastroenterol Hepatol; 2020 May; 18(5):1142-1151.e10. PubMed ID: 31446181 [TBL] [Abstract][Full Text] [Related]
14. Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis. Feagan BG; Schreiber S; Wolf DC; Axler JL; Kaviya A; James A; Curtis RI; Geransar P; Stallmach A; Ehehalt R; Bokemeyer B; Khalid JM; O'Byrne S Inflamm Bowel Dis; 2019 May; 25(6):1028-1035. PubMed ID: 30365009 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis. Sandborn WJ; Baert F; Danese S; Krznarić Ž; Kobayashi T; Yao X; Chen J; Rosario M; Bhatia S; Kisfalvi K; D'Haens G; Vermeire S Gastroenterology; 2020 Feb; 158(3):562-572.e12. PubMed ID: 31470005 [TBL] [Abstract][Full Text] [Related]
16. Vedolizumab as induction and maintenance therapy for ulcerative colitis. Feagan BG; Rutgeerts P; Sands BE; Hanauer S; Colombel JF; Sandborn WJ; Van Assche G; Axler J; Kim HJ; Danese S; Fox I; Milch C; Sankoh S; Wyant T; Xu J; Parikh A; N Engl J Med; 2013 Aug; 369(8):699-710. PubMed ID: 23964932 [TBL] [Abstract][Full Text] [Related]
17. Clinical Outcomes and Response Predictors of Vedolizumab Induction Treatment for Korean Patients With Inflammatory Bowel Diseases Who Failed Anti-TNF Therapy: A KASID Prospective Multicenter Cohort Study. Kim J; Yoon H; Kim N; Lee KM; Jung SA; Choi CH; Kim ES; Jung Y; Eun CS; Kim TO; Kang SB; Kim YS; Seo GS; Lee CK; Im JP; Park SJ; Park DI; Ye BD Inflamm Bowel Dis; 2021 Nov; 27(12):1931-1941. PubMed ID: 33501935 [TBL] [Abstract][Full Text] [Related]
18. Sustained Corticosteroid-Free Clinical Remission During Vedolizumab Maintenance Therapy in Patients with Ulcerative Colitis on Stable Concomitant Corticosteroids During Induction Therapy: A Post Hoc Analysis of GEMINI 1. Loftus EV; Sands BE; Colombel JF; Dotan I; Khalid JM; Tudor D; Geransar P Clin Exp Gastroenterol; 2020; 13():211-220. PubMed ID: 32606883 [TBL] [Abstract][Full Text] [Related]